Indian generic drug manufacturer Natco Pharma Limited has filed an application before the Controller of Patents seeking compulsory license to produce the drug 'Baricitinib' which is used for treatment of COVID-19.Natco filed application under Section 92 read with 92 of the Patents Act seeking compulsory license to produce 'Baricitinib' at an affordable rate amid the second wave of the. Indian …
